Abstract:When SARS‐CoV‐2 enters inside the cell by fusion process it encodes few proteins including main protease with the help of cellular ribosomes. This main protease mediates the maturation cleavage of polyproteins at 11 different regions, which is a notable step in virus's life cycle. SARS‐CoV‐2 Mpro is mainly a homo‐dimeric enzyme consisting of three domains. The large substrate‐binding site with a catalytic dyad of His41 and Cys145 is located between chymotrypsin‐like domains I and picornavirus 3C protease‐like domain II. Inhibition of this substrate binding site disrupt the replication process. But being large substrate‐binding site, peptide is more suitable than small molecules for inhibiting this crucial site. The outcome of this computational study displays that the attachment of peptide with Mpro protease can be a good strategy to inhibit the substrate‐binding site which may lead to disruption of replication process of SARS CoV‐2. The COVID‐19 pandemic has been a public health emergency, with deadly forms constantly emerging around the world, highlighting the dire need for highly effective antiviral therapeutics. Peptide therapeutics show significant potential for this viral disease due to their efficiency, safety, and specificity. Here, two thousand seven hundred eight antibacterial peptides were screened computationally targeting the Main protease (Mpro) of SARS CoV‐2. Six top‐ranked peptides according to their binding scores, binding pose were investigated by molecular dynamics to explore the interaction and binding behavior of peptide‐Mpro complexes. The structural and energetic characteristics of Mpro‐DRAMP01760 and Mpro‐DRAMP01808 complexes fluctuated less during a 250 ns MD simulation. In addition, three peptides (DRAMP01760, DRAMP01808, and DRAMP01342) bind strongly to Mpro protein, according to the free energy landscape and principal component analysis. Peptide helicity and secondary structure analysis are in agreement with our findings. Interaction analysis of protein‐peptide complexes demonstrated that Mpro's residue CYS145, HIS41, PRO168, GLU166, GLN189, ASN142, MET49, and THR26 play significant contributions in peptide‐protein attachment. Binding free energy analysis (MM‐PBSA) demonstrated the energy profile of interacting residues of Mpro in peptide‐Mpro complexes. To summarize, the peptides DRAMP01808 and DRAMP01760 may be highly Mpro specific, resulting disruption in a viral replication and transcription. The results of this research are expected to assist future research toward the development of antiviral peptide‐based therapeutics for Covid‐19 treatment.

Exploiting Hydrophobic Amino Acid Scanning to Develop Cyclic Peptide Inhibitors of the SARS‐CoV‐2 Main Protease with Antiviral Activity

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Structure-Based Design of a Cyclic Peptide Inhibitor of the SARS-CoV-2 Main Protease

Design, Synthesis, and Unprecedented Interactions of Covalent Dipeptide-Based Inhibitors of SARS-CoV-2 Main Protease and its Variants Displaying Potent Antiviral Activity

Molecular Modelling, Synthesis, and In-Vitro Assay to Identify Potential Antiviral Peptides Targeting the 3-Chymotrypsin-Like Protease of SARS-CoV-2

Design of novel and highly selective SARS-CoV-2 main protease inhibitors

Large scale peptide screening against main protease of SARS CoV‐2

De Novo Discovery of a Noncovalent Cell-Penetrating Bicyclic Peptide Inhibitor Targeting SARS-CoV-2 Main Protease

Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development

Exploiting high-energy hydration sites for the discovery of potent peptide aldehyde inhibitors of the SARS-CoV-2 main protease with cellular antiviral activity

Synthesis and biological evaluation of novel Peptidomimetic inhibitors of the coronavirus 3C-like protease

Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease

De novo Design of SARS-CoV-2 Main Protease Inhibitors

Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors

Structural and mechanistic insights into Main protease (Mpro) dimer interface destabilization inhibitor: Unveiling new therapeutic avenues against SARS-CoV-2

An Enhanced Hybrid Screening Approach to Identify Potent Inhibitors for the SARS-CoV-2 Main Protease From the NCI Compound Library

Progress of SARS‐CoV‐2 Main Protease Peptide‐like Inhibitors

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease

Design, Synthesis, X-ray Crystallography, and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease

Azapeptide activity-based probes for the SARS-CoV-2 main protease enable visualization of inhibition in infected cells